Microbial drug resistance imposes an increasing threat to human and animal health and the development of new drugs to control bacterial infections is therefore urgently needed. The overall objective of this project is to exploit a new class of bacterial targets called two-component systems (TCS) for the development of novel antibacterial and drugs that specifically target the mechanisms by which bacteria establish infection in the host. This objective will be achieved by targeting pan-European critical mass, expertise and support to understanding of the structure, function and biological diversity of these targets. By the end of the project we will expect to have selected appropriate targets and have developed selective assays for inhibitors of those targets that can be used for high throughput screening in the pharmaceutical industry.
Funding SchemeCSC - Cost-sharing contracts